Full video transcriptClick to expand
Auto-generated transcript of @.dreamingdiana's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Alright, this is what I look like one month on RETA, uh, three weeks on GHK, and I think,
- 0:06I believe, I gotta double check that.
- 0:08But I started RETA end of January and it basically announced my last week.
- 0:13I can honestly say that I lost less than 10 pounds.
- 0:16Um, wasn't the ideal thing that I was wearing where I was already kind of skinny.
- 0:18It's just with PCOS, I had a lot of lower belly fat, um, and a lot of inflammation,
- 0:22and so that's what I was trying to cleanse mostly, and that's kind of what it did.
- 0:25Um, but you do have to work out for sure with RETA because I was losing more muscle than
- 0:30I was losing my fat, the visceral fat, more so, that's what I was worried about, well,
- 0:34that's what I wanted.
- 0:35Um, and that didn't really work out for me as much.
- 0:37Um, like I said, the pounds, the weight that I lost, yes, it kind of did help, but I still
- 0:41kind of have that lower fat just because of that, and yes it is only a month, so you still
- 0:44have some time to work through it.
- 0:45Um, but me, feeling the way that I was feeling overall, I think a month for me on RETA is
- 0:49good enough.
- 0:50Um, even GHK-Cu, which I'm also on, you know, my third week or so, um, and you can
- 0:55see the results with that too, because I had really bad acne and still healing, and I'm
- 0:58still going to be on it until the end of that for sure.
- 1:00I still got like me to a month left on that.
- 1:02Um, but with RETA, I was having a lot of symptoms that, you know, it's just, it was nice for
- 1:05the month that I was on it, but continuing more with it for me, personally with my body
- 1:08and all that, I just don't think it would make sense.
- 1:10Um, so far RETA has been, you know, it worked for me.
- 1:12Like, I lost less than 10 pounds, and the lower belly fat has gone down, do I still have
- 1:15it, yes.
- 1:16Um, I'm still working on that, and the thing is it is a tool, so it's not, you know, the miracle,
- 1:20uh, be all, and all, you still have to work out and eat right, and I was eating one meal
- 1:24a day, which, like, yes, it suppresses your hunger, but you still need to eat carbs, and
- 1:27I wasn't doing that.
- 1:28And that was also only working three days, working out three days a week for an hour, if that,
- 1:31you know, if something is I wasn't, I had three jobs, so, um, but yeah, like, no, overall,
- 1:35it is very useful, and I highly recommend it, especially with people with PCOS and, you
- 1:39know, pre-diabetes or diabetics, obviously, I got a check with their doctor and all that,
- 1:42but, um, yeah, for me and my goals, one month seems to be just fine.
- 1:47Um, but overall, yeah, it's been more beneficial than anything, and I do highly recommend it
- 1:50for people with PCOS, for sure, because I lost the weight and my acne has gone down.
- 1:53Oh, back, can you come pick up your goals?
- 1:57Uh, yeah.
Peptide therapy TikTok claims: what the evidence actually supports
Quick answer
The creator used what appears to be compounded retatrutide, a non-approved triple GIP/GLP-1/glucagon receptor agonist, for 30 days alongside GHK-Cu, a copper peptide, to address PCOS-associated visceral adiposity and acne. She reports modest weight loss under 10 pounds and partial reduction in lower abdominal fat, consistent with early-phase GLP-1 mechanism effects, but also experienced unspecified adverse symptoms and likely muscle loss secondary to severe caloric restriction. No clinical oversight, lab monitoring, or baseline metabolic testing was described.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Peptide therapy TikTok claims: what the evidence actually supports, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial
Primary human trial source for retatrutide obesity efficacy and safety discussions.
PubMed
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease
Used when retatrutide pages touch liver-fat, MASLD, and metabolic outcomes.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Peptide therapy TikTok claims: what the evidence actually supports is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Peptide therapy TikTok claims: what the evidence actually supports" from dieanasem. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator used what appears to be compounded retatrutide, a non-approved triple GIP/GLP-1/glucagon receptor agonist, for 30 days alongside GHK-Cu, a copper peptide, to address PCOS-associated visceral adiposity and acne.
The reason this review is not generic is the source wording and the canonical claim label "peptides tiktok 7615458334648421662." In this clip, the useful excerpt is: "Alright, this is what I look like one month on RETA, uh, three weeks on GHK, and I think, I believe, I gotta double check that." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), Discontinuing glucagon-like peptide-1 receptor agonists and body habitus (2025), and Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition (2025), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator used what appears to be compounded retatrutide, a non-approved triple GIP/GLP-1/glucagon receptor agonist, for 30 days alongside GHK-Cu, a copper peptide, to address PCOS-associated visceral adiposity and acne.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator used what appears to be compounded retatrutide, a non-approved triple GIP/GLP-1/glucagon receptor agonist, for 30 days alongside GHK-Cu, a copper peptide, to address PCOS-associated visceral adiposity and acne. She reports modest weight loss under 10 pounds and partial reduction in lower abdominal fat, consistent with early-phase GLP-1 mechanism effects, but also experienced unspecified adverse symptoms and likely muscle loss secondary to severe caloric restriction. No clinical oversight, lab monitoring, or baseline metabolic testing was described.
- Retatrutide showed 17.5% body weight reduction at 48 weeks in a Phase 2 NEJM trial (Jastreboff et al., 2023), but no Phase 3 data exists and it is not FDA-approved as of early 2025.
- Compounded retatrutide sold through peptide channels is not equivalent to the drug tested in clinical trials, with no regulatory verification of purity or dosing accuracy.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Retatrutide showed 17.5% body weight reduction at 48 weeks in a Phase 2 NEJM trial (Jastreboff et al., 2023), but no Phase 3 data exists and it is not FDA-approved as of early 2025.
- Compounded retatrutide sold through peptide channels is not equivalent to the drug tested in clinical trials, with no regulatory verification of purity or dosing accuracy.
- Lean mass loss during GLP-1-assisted weight loss is a documented clinical concern, worsened significantly by very low calorie intake and insufficient protein, as seen in Wilding et al. (2021, NEJM).
- GLP-1 receptor agonists have shown metabolic benefit in PCOS (Tang et al., 2022, Reproductive BioMedicine Online), but retatrutide specifically has no published PCOS trial data.
- GHK-Cu has preclinical anti-inflammatory and collagen-remodeling evidence in skin (Pickart and Margolina, 2018, Cosmetics), but controlled acne trials are absent and attributing acne improvement to GHK-Cu alone after three weeks is not supportable.
- Unspecified symptoms leading to early discontinuation are a red flag that was not addressed in the video, and the GLP-1 class carries documented risks including gastrointestinal events and theoretical thyroid C-cell concerns.
- Anyone with PCOS interested in GLP-1-class treatment has FDA-approved, clinically monitored options available through licensed providers, which carry a meaningfully different safety and accountability profile than compounded peptide sourcing.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @.dreamingdiana actually say?
She used something called RETA for one month and GHK-Cu for about three weeks, primarily to address lower belly fat and inflammation associated with PCOS. She lost "less than 10 pounds," noticed some reduction in lower abdominal fat, and saw improvement in acne she attributes to GHK-Cu. She also flagged a real problem she ran into: eating one meal a day while on RETA led to muscle loss rather than fat loss. She stopped RETA after a month due to symptoms she doesn't fully describe. Her framing is relatively grounded, calling it "a tool" rather than a miracle, and she mentions the need to work out and eat properly. She does recommend it specifically for people with PCOS and pre-diabetes, while noting they should check with a doctor.
Does the science back this up?
Partially, but with some significant gaps. "RETA" appears to refer to retatrutide, a triple GIP/GLP-1/glucagon receptor agonist. It is not FDA-approved as of early 2025. GHK-Cu is a copper peptide with a more established research base, though mostly preclinical. Here is where each claim lands.
On retatrutide: a Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023) showed 17.5% body weight reduction at 48 weeks with the highest dose tested. That is meaningful data, but it is from a controlled trial, not a compounded peptide used for one month. The fat distribution effects she describes, specifically visceral fat reduction, are plausible given the mechanism, but one month is a very short window for that outcome to fully materialize.
On GHK-Cu and acne: the evidence here is weaker. Pickart and Margolina (2018, Cosmetics) reviewed GHK-Cu's anti-inflammatory and tissue-remodeling properties in skin, but controlled trials specifically for acne are limited. Preclinical data is promising. Calling this a three-week acne result is plausible but not well-supported by clinical trials.
On PCOS and visceral fat: GLP-1 receptor agonists as a class have shown benefit for PCOS-related metabolic dysfunction. A meta-analysis by Tang et al. (2022, Reproductive BioMedicine Online) found GLP-1 agonists reduced BMI and fasting insulin in PCOS patients. Retatrutide's triple-receptor activity theoretically extends this benefit, but PCOS-specific data for retatrutide specifically does not exist yet.
What did they get wrong (or right)?
She got the muscle-loss concern right. Eating one meal a day while using a potent appetite suppressant is a real problem. GLP-1-based drugs cause weight loss through caloric restriction, and without adequate protein intake and resistance training, lean mass loss is a documented side effect. A study by Wilding et al. (2021, NEJM) on semaglutide noted that roughly 40% of weight lost included lean mass. She figured this out empirically, which is actually a useful data point for her audience.
What she got wrong, or at least incomplete: she recommends RETA for people with PCOS and pre-diabetes without any meaningful discussion of the risks. Retatrutide is not approved, has not been studied in PCOS populations specifically, and the compounded versions circulating through peptide channels are not equivalent to the drug tested in trials. Pancreatitis risk, thyroid C-cell concerns (seen across the GLP-1 class), and gastrointestinal side effects deserve mention. The "symptoms" she references but never names is a gap that matters when you are recommending something to 9,700 people.
Her instinct to stop after one month because her body was giving her signals is reasonable. Her framing of the result as modest and partial is also honest. Credit where it is due: she did not overclaim dramatic transformation.
What should you actually know?
Retatrutide is a triple agonist that showed strong clinical results in Phase 2 trials, but it is not approved and the compounded peptide versions sold online are not the same compound that was studied. There is no regulatory pathway confirming purity, dosing accuracy, or safety of those products. If you have PCOS and are interested in GLP-1-class medications, there are approved options, semaglutide and tirzepatide, with actual prescribing data and safety monitoring attached to them.
GHK-Cu has a reasonable evidence base for skin-related applications, primarily anti-inflammatory and collagen-stimulating effects, but "three weeks and my acne improved" is anecdote, not clinical evidence. It could be the peptide. It could be dietary changes from appetite suppression. It could be reduced inflammation from weight loss itself. You cannot isolate the variable here.
The OMAD (one meal a day) approach while using appetite-suppressing peptides is a pattern that keeps appearing in peptide content, and it is worth flagging plainly: inadequate caloric and protein intake during pharmacologically-driven weight loss accelerates lean mass loss. This is not a minor inconvenience. Muscle loss has long-term metabolic consequences, particularly for insulin sensitivity, which is already compromised in PCOS.
Anyone considering retatrutide specifically should know: no Phase 3 data exists, no long-term safety profile exists, and the PCOS indication she is recommending it for has not been studied in a controlled setting for this compound.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
dieanasem · TikTok creator
9.7K views on this video
Peptide therapy TikTok claims: what the evidence actually supports
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about retatrutide showed 17.5% body weight reduction at 48 weeks in?
Retatrutide showed 17.5% body weight reduction at 48 weeks in a Phase 2 NEJM trial (Jastreboff et al., 2023), but no Phase 3 data exists and it is not FDA-approved as of early 2025.
What does the video say about compounded retatrutide sold through peptide channels?
Compounded retatrutide sold through peptide channels is not equivalent to the drug tested in clinical trials, with no regulatory verification of purity or dosing accuracy.
What does the video say about lean mass loss during glp-1-assisted weight loss?
Lean mass loss during GLP-1-assisted weight loss is a documented clinical concern, worsened significantly by very low calorie intake and insufficient protein, as seen in Wilding et al. (2021, NEJM).
What does the video say about glp-1 receptor agonists have shown metabolic benefit in pcos (tang?
GLP-1 receptor agonists have shown metabolic benefit in PCOS (Tang et al., 2022, Reproductive BioMedicine Online), but retatrutide specifically has no published PCOS trial data.
What does the video say about ghk-cu has preclinical anti-inflammatory?
GHK-Cu has preclinical anti-inflammatory and collagen-remodeling evidence in skin (Pickart and Margolina, 2018, Cosmetics), but controlled acne trials are absent and attributing acne improvement to GHK-Cu alone after three weeks is not supportable.
What does the video say about unspecified symptoms leading to early discontinuation?
Unspecified symptoms leading to early discontinuation are a red flag that was not addressed in the video, and the GLP-1 class carries documented risks including gastrointestinal events and theoretical thyroid C-cell concerns.
Sources & references
- [1]Jastreboff et al., 2023)
- [2]Tang et al. (2022)
- [3]Wilding et al. (2021)
- [4]Pickart and Margolina (2018)
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by dieanasem, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.